Notably, the degree of increase of MoCA was significant and it was much higher between Visit 3 and Visit 1 in the CMA group than in the placebo group, suggesting the Parkinson’s disease patients might benefit from CMA treatment after 84 days of treatment. Here, DOCK3 is linked to Parkinson disease.